Built to Scale, Positioned to Sell

​Manufacturing readiness is one of the clearest signals of whether a MedTech company is truly built to scale—and ultimately, to sell. For early-stage life science and medical device ventures, initial decisions around product design, quality systems, and supply chain planning can either accelerate commercialization or create devastating, costly barriers to an exit.

​Presented by PDV MedTech, and University Lab Partners, this panel brings together the vital pillars of the MedTech ecosystem: investment banking, advanced manufacturing leadership, and venture acceleration. Together, our experts will explore how operational readiness directly impacts valuation, investor confidence, and M&A diligence outcomes. Attendees will gain actionable insights into bridging the gap between clinical validation and commercial scalability, minimizing technical debt, and making strategic choices today that maximize optionality and exit value tomorrow.

Panelists Include:

​Bryant Grigsby is the CEO of PDV MedTech, formerly known as Phoenix DeVentures, a full-service medical device design and manufacturing firm. Following the company’s acquisition by INDO-MIM in 2025, Grigsby continues to lead the executive team, focusing on scaling production and automation for Class I, II, and III medical devices. He is also a frequent speaker at global life science and MedTech innovation summits.

​Caroline Borowski is a Vice President in the Healthcare Investment Banking group at J.P. Morgan. She joined the team in 2018 and has 8 years of experience in healthcare investment banking. She is focused on the medical technology sector with experience across corporate finance, mergers and acquisitions as well as equity and debt financings. She graduated from Northwestern University with a M.S. in Computer Science and a B.S. in Industrial Engineering.

​Tomer Stavitsky is a seasoned MedTech business executive leading corporate development, strategy, and M&A across the healthcare and life sciences industry. He currently serves as Senior Vice President and Chief Corporate Development Officer at Omnicell, where he leads the company’s corporate development, investments, and M&A program. Prior to Omnicell, Tomer led corporate development initiatives at companies including Ginkgo Bioworks and Allurion Technologies, and previously held corporate development roles at Intuitive Surgical, Johnson & Johnson, and Pfizer. He also worked with startups through MedTech Innovator and independently, advising on fundraising, partnerships, M&A, and go-to-market strategy.

​Moderator:

​Charla Triplett is an experienced MedTech executive, investor, and innovation leader who serves as the Head of Strategy, Partnerships & Growth at University Lab Partners and is a Co-founder of Suncoast Ventures. With over 25 years of experience in bioengineering and venture acceleration, she specializes in bridging the gap between academia, life science startups, and commercialization. Currently, she also leads the digital health spin-out Spine by Design as its CEO.